BioCentury | Jun 5, 2020
Finance

In age of megafunds, Atlas stays the course with $400M twelfth venture fund

...He also had observer status at oncolytic immunotherapy play Replimune Inc. (NASDAQ:REPL) and autoimmune company Delinia Inc....
...IPO came less than three years after its Atlas-backed series A, while Celgene Corp. acquired Delinia...
BioCentury | Nov 13, 2019
Financial News

As resources diversify, Sofinnova Partners stays course with new €333M fund

...with Fund VIII “showing a multiple of that today.” A 2015 investment in autoimmune company Delinia Inc....
BioCentury | Oct 17, 2019
Financial News

As resources diversify, Sofinnova Partners stays course with new €333M fund

...with Fund VIII “showing a multiple of that today.” A 2015 investment in autoimmune company Delinia Inc....
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...monotherapy there is very little.” Gladstone was a board observer for IL-2 focused autoimmune play Delinia Inc....
BioCentury | Oct 28, 2017
Finance

Big cap bloodletting

...only other large takeout by a big cap biotech was Celgene’s acquisition of autoimmune company Delinia Inc....
BioCentury | Oct 9, 2017
Company News

Management tracks: BMS, Amicus, Armo, Noxxon

...was a venture partner at Atlas Venture , as well as president and CEO at Delinia Inc....
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...said Wu. Wu was SVP of preclinical and early clinical development at Boston autoimmune play Delinia Inc....
BioCentury | Sep 29, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...exacerbate disease. Other companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc....
...Biosciences Inc. (NASDAQ:CLBS), Iltoo Pharma (Paris, France) and TxCell S.A. (Euronext:TXCL). Celgene Corp. (NASDAQ:CELG) acquired Delinia...
...Research Institute , Seattle, Wash. Business: Gene/Cell therapy, Autoimmune Mary Romeo Bayer AG Caladrius Biosciences Inc. Celgene Corp. CRISPR Therapeutics AG Delinia Inc. Iltoo...
BioCentury | Sep 27, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...exacerbate disease. Other companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc....
...Biosciences Inc. (NASDAQ:CLBS), Iltoo Pharma (Paris, France) and TxCell S.A. (Euronext:TXCL). Celgene Corp. (NASDAQ:CELG) acquired Delinia...
BioCentury | Jul 28, 2017
Company News

Nektar and Lilly partner to co-develop autoimmune candidate

...IL-2 receptor agonist. In January, Celgene Corp. (NASDAQ:CELG) gained DEL106 when it acquired autoimmune company Delinia Inc....
...Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Autoimmune Mary Romeo NKTR-358 Celgene Corp. Delinia Inc. Eli...
Items per page:
1 - 10 of 19
BioCentury | Jun 5, 2020
Finance

In age of megafunds, Atlas stays the course with $400M twelfth venture fund

...He also had observer status at oncolytic immunotherapy play Replimune Inc. (NASDAQ:REPL) and autoimmune company Delinia Inc....
...IPO came less than three years after its Atlas-backed series A, while Celgene Corp. acquired Delinia...
BioCentury | Nov 13, 2019
Financial News

As resources diversify, Sofinnova Partners stays course with new €333M fund

...with Fund VIII “showing a multiple of that today.” A 2015 investment in autoimmune company Delinia Inc....
BioCentury | Oct 17, 2019
Financial News

As resources diversify, Sofinnova Partners stays course with new €333M fund

...with Fund VIII “showing a multiple of that today.” A 2015 investment in autoimmune company Delinia Inc....
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

...monotherapy there is very little.” Gladstone was a board observer for IL-2 focused autoimmune play Delinia Inc....
BioCentury | Oct 28, 2017
Finance

Big cap bloodletting

...only other large takeout by a big cap biotech was Celgene’s acquisition of autoimmune company Delinia Inc....
BioCentury | Oct 9, 2017
Company News

Management tracks: BMS, Amicus, Armo, Noxxon

...was a venture partner at Atlas Venture , as well as president and CEO at Delinia Inc....
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...said Wu. Wu was SVP of preclinical and early clinical development at Boston autoimmune play Delinia Inc....
BioCentury | Sep 29, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...exacerbate disease. Other companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc....
...Biosciences Inc. (NASDAQ:CLBS), Iltoo Pharma (Paris, France) and TxCell S.A. (Euronext:TXCL). Celgene Corp. (NASDAQ:CELG) acquired Delinia...
...Research Institute , Seattle, Wash. Business: Gene/Cell therapy, Autoimmune Mary Romeo Bayer AG Caladrius Biosciences Inc. Celgene Corp. CRISPR Therapeutics AG Delinia Inc. Iltoo...
BioCentury | Sep 27, 2017
Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

...exacerbate disease. Other companies pursuing ways of selectively enhancing Treg activity in autoimmune diseases include Delinia Inc....
...Biosciences Inc. (NASDAQ:CLBS), Iltoo Pharma (Paris, France) and TxCell S.A. (Euronext:TXCL). Celgene Corp. (NASDAQ:CELG) acquired Delinia...
BioCentury | Jul 28, 2017
Company News

Nektar and Lilly partner to co-develop autoimmune candidate

...IL-2 receptor agonist. In January, Celgene Corp. (NASDAQ:CELG) gained DEL106 when it acquired autoimmune company Delinia Inc....
...Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Autoimmune Mary Romeo NKTR-358 Celgene Corp. Delinia Inc. Eli...
Items per page:
1 - 10 of 19